

Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX


The Eventide Gilead Fund is a diversified mutual fund that seeks to provide long-term capital appreciation. The fund primarily invests in equity securities of companies that we believe demonstrate values and business practices that are ethical, sustainable, and provide an attractive investment opportunity. The fund also seeks securities that have significant near-term appreciation potential.

TOP HOLDINGS¹

Ascendis Pharma A/S (4.88%) Rare-disease focused biopharmaceuticals	Sage Therapeutics Inc (2.97%) Treatments for central nervous system disorders
Twilio Inc (4.25%) Cloud communications platform for building SMS, voice, and messaging applications	Roper Technologies Inc (2.96%) Specialty market software and engineered solutions
The Trade Desk (4.13%) Digital advertising platform for display, social, mobile, and video campaigns	Waste Connections Inc (2.90%) Waste collection, disposal, and recycling services in U.S. and Canada
Sarepta Therapeutics Inc (3.72%) Precision genetic medicines to treat rare neuromuscular diseases	Wayfair Inc (2.83%) Online sales of furniture and home decor
Zogenix Inc (3.29%) Therapies for central nervous system disorders and rare diseases	Palo Alto Networks Inc (2.21%) Integrated cloud and network security solutions

Growth of \$10,000^{2,3}

Jul 2008–Jun 2019



Percent Returns by Year^{2,3}

	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Eventide Gilead Fund	46.08	18.46	0.25	18.15	52.93	17.86	-2.15	0.90	32.85	-2.55
S&P 500 Total Return Index ⁴	26.46	15.06	2.11	16.00	32.39	13.69	1.38	11.96	21.83	-4.38
Russell Midcap Growth Index ⁴	46.29	26.38	-1.65	15.81	35.74	11.90	-0.20	7.33	25.27	-4.75

Fund Returns³

30 Jun 2019

	YTD	1-year	3-year ⁵	5-year ⁵	10-year ⁵	Since Inception ⁵	Inception Date ⁵
<i>Eventide Gilead Fund</i>							
Class N	31.86%	16.43%	23.47%	12.51%	17.50%	15.50%	7/8/2008
Class A without load	31.80%	16.36%	23.40%	12.45%	—	18.05%	10/28/2009
Class A with 5.75% load	24.24%	9.66%	20.99%	11.12%	—	17.33%	10/28/2009
Class C	31.31%	15.51%	22.49%	11.61%	—	17.15%	10/28/2009
Class I	31.98%	16.66%	23.72%	12.74%	—	16.69%	2/2/2010
<i>Benchmarks</i>							
S&P 500 Total Return Index ⁴	18.54%	10.42%	14.19%	10.71%	14.70%	10.26%	7/8/2008
Russell Mid-Cap Growth Index ⁴	26.08%	13.94%	16.49%	11.10%	16.02%	11.11%	7/8/2008

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses, or sales charges. To obtain the most recent month-end performance information and a current Eventide Gilead Fund prospectus please call the fund toll free at 1-877-771-EVEN (3836).

1. Does not include money market funds. Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

2. These charts compare the Eventide Gilead Fund Class N's performance to index performance over the periods shown. Performance will differ for other fund classes, based upon fees and commissions. The Growth of \$10,000 Chart assumes Class N's inception date of July 8, 2008 for the indices.

3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.

4. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. It is not an investment product available for purchase. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The volatility of the indices may be materially different than that of the fund, and investors should not expect the fund to achieve the same results as the indices listed.

5. Performance figures for periods greater than 1 year are annualized. The fund's share classes have different inception dates. Class N has an inception date of July 8, 2008. Class A and Class C have an inception date of October 28, 2009. Class I has an inception date of February 2, 2010. The indices assume an inception date of July 8, 2008.

Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX

OVERVIEW

Fund	Nasdaq	Maximum Sales Charge	12b-1 Fees	Total Expenses	Inception Date
Class A	ETAGX	Front-end ¹ : 5.75%	0.25%	1.45%	10/28/2009
Class C	ETCGX	None	1.00%	2.20%	10/28/2009
Class I	ETILX	None	0.00%	1.20%	2/2/2010
Class N	ETGLX	None	0.20%	1.40%	7/8/2008


Minimum Investment: \$1,000 or \$100 with Automatic Investment Plan (Class A, C, N), \$100,000 (Class I)
 Net assets: \$2.65 billion

MANAGER

Dr. Finny Kuruvilla has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women's Hospital and Children's Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.




Portfolio Composition² % of portfolio



Equity market capitalization: \$15.9B average, \$7.9B median
 Average annual turnover range: 24%–28% (2016–2018)³

Sector Allocation⁴ % of portfolio



Market Risk⁵

	Std. Dev.		Beta		Alpha		R-Squared	
	3-year	Inception ⁶	3-year	Inception ⁶	3-year	Inception ⁶	3-year	Inception ⁶
Eventide Gilead N	16.83	19.18	1.13	1.05	6.92	4.72	67.26	69.13
Russell Midcap Growth Index	14.39	17.99	1.12	1.13	0.77	-0.10	90.51	90.67
S&P 500 Total Return Index	12.19	15.11	1.00	1.00	—	—	100.00	100.00

1. Class A is also subject to a maximum deferred sales charge of 1.00%. This and other expenses that apply to a continued investment in the fund are described in the fund's prospectus.
 2. Market cap definitions are now based on those used by Morningstar, where Giant Cap are those companies that account for the top 40% of capitalization, Large Cap is the next 30%, Mid Cap is the next 20%, Small Cap is the next 7%, and Micro Cap is the last 3%. Fact sheets dated before June 30, 2018 defined \$10 billion or greater as Large Cap; greater than \$1 billion was Mid Cap; and less than \$1 billion was Small Cap. The definition was updated to account for industry changes, and should not imply a strategic change in the management of the fund's portfolio.
 3. Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year ending on June 30th. A higher portfolio turnover

may indicate higher transaction costs for the fund, and may result in higher taxes for investors. The range shows the highest and lowest turnover ratio reported in the Annual Report during the last three years.
 4. The fund may not invest 25% or more, except by appreciation, of its total assets in a particular industry or group of industries. A sector is normally composed of many industry groups. Sector Allocation is subject to change at any time and should not be considered investment advice.
 5. Source: © Morningstar, Inc. (2019). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. The performance and risk factor comparisons are against

the S&P 500 Total Return Index ("Index"). Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of the fund relative to the return of the Index is a fund's alpha. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index. R-Squared measures how a fund's performance correlates with the Index's performance and it can help assess how likely it is that beta is statistically significant. Standard Deviation of return measures the amount of variation in historical performance from period to period.
 6. Annualized since inception market risk details assume inception date of August 1, 2008 and not Class N's actual inception date of July 8, 2008, as only full month data is included in the market risk calculations.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The fund's ethical values screening criteria could cause it to under perform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrials sector carry various risks including, but not limited to, risk related to debt loads and intense competition. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.

An investor should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.